Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies

NCT04170283 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT04170283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04170283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies
Lead sponsor
BeOne Medicines
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 16, 2020
Completion date
December 31, 2026
Enrollment
955 (actual)
Sites
153

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell malignancies